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Although risk prediction in individual patients with 
heart failure remains challenging, many factors have 
shown to be predictive of adverse long-term outcomes. Renal dysfunc-
tion and elevated natriuretic peptides are among the strongest 
predictors.1–3 Renal insufficiency has often been considered as 
a reduction in glomerular filtration rate (GFR) and is tradi-
tionally quantified based on serum creatinine (sCr) levels or 
equations that are derived from sCr measurements. However, 
the prognostic use of these sCr-based estimates in the chronic 
heart failure population remains inferior to GFR, directly 
quantified by 125I-iothalamate clearance, suggesting that con-
founders exist.4 Nevertheless, cardiovascular risk is believed 
to be significantly elevated below an estimated GFR of 60 mL/
min per 1.73 m2 based on these equations.5
In recent years, cystatin C (CysC) has emerged as a sensi-
tive measure of renal function. CysC is a cysteine protease 
inhibitor produced by nearly all nucleated human cells at a 
fairly constant rate (housekeeping gene) and is subsequently 
circulated in the bloodstream. Compared with creatinine, lev-
els of CysC are less influenced by age, sex, or race. Because 
of its low molecular weight (13 kDa), it is freely filtered and 
neither secreted from nor reabsorbed back into the bloodstream 
(although it is metabolized by the proximal tubular cells).6 All 
these properties render CysC a potentially better estimate of 
GFR than sCr-based estimates. In the chronic kidney disease 
population, estimates of GFR have incorporated CysC as part 
of the new equations.7 CysC has also proven to be a better pre-
dictor of mortality and cardiovascular events than sCr-based 
estimates in different populations studied (elderly, coronary 
heart disease, acute and chronic heart failure).8–11
Natriuretic peptides have found their way to everyday 
 cardiology practice for diagnostic as well as prognostic pur-
poses in patients with heart failure. Natriuretic peptides reflect 
myocardial stress and have proven to predict outcome after 
coronary syndromes, after hospitalization for acute heart fail-
ure, and in chronic heart failure.2 Despite brain natriuretic 
peptide (BNP) levels being somewhat dependent on renal 
function, BNP and CysC potentially constitute a unique bio-
marker combination for risk prediction, particularly in the set-
ting of relatively preserved renal function.
The aims of this study were as follows: (1) to examine the 
prognostic ability of CysC and derived equations, indepen-
dent of BNP, (2) to examine its incremental value over tra-
ditional markers of renal function, and (3) to investigate risk 
Background—Renal function is a strong predictor of adverse events in heart failure. Current renal function measures are 
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stratification by the combination of BNP and CysC in a chronic 
stable heart failure population undergoing cardiac evaluation.
Methods
Patient Population and Study Design 
We evaluated 823 stable patients with a clinical history of heart 
failure undergoing elective coronary angiography as part of the 
GeneBank study. GeneBank was a large prospective study, conducted 
at the Cleveland Clinic between 2001 and 2006 (NCT 00590200) 
that established a well-characterized clinical repository with clinical 
and longitudinal outcomes. Inclusion criteria were age ≥18 years and 
planned coronary angiography. There were no specific exclusion cri-
teria. All participants gave written informed consent approved by the 
Cleveland Clinic Institutional Review Board. At the time of cardiac 
catheterization, blood samples were collected, processed, and stored 
at −80°F until analyses.
Renal function was expressed as sCr, blood urea nitrogen lev-
els, CysC, and estimated GFR by the 4-variable modification of 
diet in renal disease (MDRD) equation (eGFRMDRD=186×sCr−1.154× 
age−0.203×[0.742 if women]×[1.21 if black]), the chronic kidney 
 disease epidemiology collaboration equation for CysC (eGFRCysC= 
127.7×CysC−1.17×age−0.13×[0.91 if women]×[1.06 if black]), or 
the eGFR
sCr+CysC equation (eGFRsCr+CysC=177.6×sCr−0.65×CysC−0 57× 
age−0.20×[0.82 if women]×[1.11 if black]). Preserved and impaired 
renal function were defined as eGFRMDRD ≥60 mL/min per 1.73 m2
and eGFRMDRD <60 mL/min per 1.73 m2, respectively.
The end point of this study was a composite of major adverse car-
diovascular events (MACE), including all-cause mortality, nonfatal 
myocardial infarction (MI), and nonfatal cerebrovascular accident. 
Nonfatal events were defined as MI or cerebrovascular accident in 
patients who survived at least 48 hours after the onset of symptoms. 
These clinical outcomes were prospectively ascertained during the 
ensuing 3 years for all subjects after enrollment, adjudicated, and 
verified by source documentation.
CysC Assay
Plasma CysC level was determined with a particle-enhanced immuno-
turbidimetric immunoassay on the Architect ci8200 platform (Abbott 
Laboratories, Abbott Park, IL). Briefly, latex particles are coated with 
antihuman CysC antibody and agglutinated with CysC present in the 
patient’s sample. The result is a change in absorbance, which is pro-
portional to the amount of CysC present in the sample. The analytical 
range spans 0.05 mg/L to the highest calibration point. Intra- and inter-
assay coefficients are 3.1% and 6%, respectively. BNP, high- sensitivity 
C-reactive protein (hsCRP), sCr, blood urea nitrogen, fasting blood
glucose, and lipid profiles were all measured by clinically approved as-
says on the same platform. The intra- and interassay coefficients were, 
respectively, 0.9% and 0.8% for blood urea nitrogen, 1.7% and 1% for
sCr, 2.6% and 3.5% for BNP, and 4% and 2.4% for hsCRP.
Statistical Analyses 
Continuous variables were expressed as mean±SD if normally distrib-
uted or as median and interquartile range for non-normally distributed 
data. Categorical data were summarized as proportions and frequen-
cies. Baseline characteristics between patients with preserved and 
decreased renal function were compared using the Student t test, the 
Wilcoxon rank-sum test, or the χ2 test, as appropriate. The Spearman 
rank correlation method was used as a nonparametric measure of as-
sociation for correlations between CysC and the different measures 
of renal function (sCr, blood urea nitrogen, eGFR equations). Areas 
under the receiver operating characteristic curves (C-statistics) for the 
prediction of MACE were compared between different measures of 
renal function, and net reclassification improvement was calculated. 
Univariate Cox proportional hazard models were used to evaluate the 
association of different measures of renal function along other vari-
ables with the composite outcome. Measures of renal function were 
entered as continuous variables (logarithmic transformed when non-
normally distributed), categorized in quartiles. Because sCr levels 
differ substantially between sexes, sex-specific quartiles for sCr were 
used to equalize the distribution of men and women. Afterward, 2 types 
of multivariate Cox proportional hazard models were constructed: a 
shorter model, using one measure of renal function in combination with 
BNP, and a longer model, with a measure of renal function adjusted for 
all variables with P<0.05 in univariate analysis. The 3-year outcome 
was evaluated by Kaplan-Meier survival analyses, using the aforemen-
tioned quartiles. Differences between groups were evaluated with the 
log-rank test. Statistical significance was set at a 2-tailed P<0.05. All 
statistical analyses were performed using JMP Pro 9.0 (SAS Institute, 
Cary, NC). All authors had full access to all the data in the study and 
take responsibility for the integrity of data and accuracy of data analy-
sis. All authors have read and agree to the article as written.
Results
Table 1 illustrates the baseline characteristics of our study 
population, which included 35% of subjects with left 
ventricular ejection fraction >50%. In our study cohort, 208 
subjects (25%) had impaired renal function as defined by 
eGFRMDRD <60 mL/min per 1.73 m2. Subjects with impaired 
renal function were likely older, women, with more comor-
bid conditions and higher median BNP levels (Table 1). CysC 
levels demonstrated a non-normal distribution (Figure 1), with 
a median level of 1.11 mg/L (interquartile range, 0.92–1.41 
mg/L). As expected, CysC had a strong correlation with other 
markers of renal function. However, in the subgroup with pre-
served renal function, such correlations were less robust with 
non–CysC-based measures of renal function (online-only 
Data Supplement Table). There were no significant differ-
ences in baseline CysC levels between those with impaired 
versus preserved left ventricular ejection fraction.
During the 3-year follow-up period, the combined end point 
of MACE occurred in 201 (24%) patients, including 20% in 
the preserved renal function group (121 patients, 132 events: 
80 deaths, 41 MI, and 11 cerebrovascular accidents) and 39% 
in the impaired renal function group (80 patients, 93 events: 62 
deaths, 25 MI, and 6 cerebrovascular accidents). Areas under 
the receiver operating characteristic curves for CysC and CysC-
based GFR estimations are significantly better than eGFRMDRD, 
both in the total cohort and in the subgroup of patients with 
eGFRMDRD ≥60 mL/min per 1.73 m2 but not in patients with
eGFRMDRD <60 mL/min per 1.73 m2 (Table 2). Nevertheless, in 
the eGFRMDRD ≥60 mL/min per 1.73 m2 group, net reclassifica-
tion improvement (compared with eGFRMDRD) was 22.2% with 
CysC, 22.8% with eGFRCysC, and 22.2% with eGFRsCr+CysC (all 
P<0.001). In univariate analysis, elevated levels of all renal 
measures were significantly associated with higher risks for 
the combined outcome in the overall cohort, both when entered 
as a continuous variable and when divided in quartiles (Table 3 
and Figure 2). Age, body mass index, diabetes mellitus, coro-
nary artery disease, hemoglobin, hsCRP, and BNP were also 
significantly associated with risk of future MACE in univariate 
analysis (data not shown). Increasing quartiles of CysC and 
decreasing quartiles for eGFRCysC demonstrated progressively 
higher risk of future MACE (Figure 3). In particular, by adjust-
ing for age, sex, and race in the eGFRCysC equation, there was 
a better separation of patients with higher eGFRCysC values. 
However, in an analysis with covariate information (BNP, age, 
body mass index, history of coronary artery disease, history of 
diabetes mellitus, hemoglobin, and hsCRP), the difference in 
C-statistics was not significant anymore.
Figure 2 also demonstrates that, when looking at eGFRM-
DRD, the risk of MACE seems to increase only when eGFRMDRD  
<60 mL/min per 1.73 m2, in agreement with classic teaching. 
But when patients are stratified by CysC or derived equation, 
the risk of MACE seems to increase earlier and looks more 
like a continuum. Fifty-two percent (212/409 subjects) in the 
2 higher CysC quartiles and 67% (415/617 subjects) in the 3 
lower eGFRCysC quartiles had eGFRMDRD ≥60 mL/min per 1.73 m2
Table 1. Baseline Characteristics
Total Cohort 
(n=823)
eGFRMDRD ≥60 mL/min 
per 1.73 m2 
(n=615)
eGFRMDRD <60 mL/min 
per 1.73 m2 
(n=208) P  Value*
Demographics
Age, y 66±11 65±11 71±9 <0.0001
Male sex, % 60 64 48 <0.0001
BMI, kg/m2 29.5±6.7 29.7±6.7 28.9±6.6 0.12
Comorbidities
Diabetes mellitus, % 29 23 45 <0.0001
Hypertension, % 76 72 86 <0.0001
Hyperlipidemia, % 80 80 80 0.68
Current smoker, % 12 13 8 0.05
CAD, % 76 74 84 0.002
Echocardiographic data
 LVEF, % 35 (25–55) 35 (25–50) 40 (25–55) 0.10
Laboratory data
Urea, mg/dL 21 (16–27) 19 (15–23) 35 (27–44) <0.0001
Creatinine, mg/dL 0.94 (0.8–1.17) 0.87 (0.76–1.15) 1.41 (1.22–1.81) <0.0001
Cystatin C, mg/dL 1.11 (0.92–1.41) 1.01 (0.88–1.18) 1.69 (1.42–2.13) <0.0001
 eGFRMDRD, mL/min per 1.73 m² 77 (60–93) 85 (72–97) 44 (36–53) <0.0001
 eGFRCysC, mL/min per 1. 73m² 63 (47–80) 71 (58–84) 37 (30–46) <0.0001
 eGFRsCr+CysC, mL/min per 1.73 m² 70 (53–86) 77 (66–90) 40 (32–48) <0.0001
BNP, pg/mL 300 (118–675) 259 (106–540) 557 (220–1108) <0.0001
Hemoglobin, g/dL 13.2±1.8 13.5±1.7 12.4±1.8 <0.0001
CRP, mg/dL 3.8 (1.6–9) 3.2 (1.4–7.8) 5.5 (2.6–14.1) <0.0001
Medications
ACE-I or ARB, % 68 68 66 0.49
β-blockers, % 67 67 66 0.67
Diuretic, % 58 53 72 <0.0001
Aspirin, % 62 62 63 0.80
Statin, % 59 60 57 0.36
eGFR indicates estimated glomerular filtration rate; BMI, body mass index; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; CysC, cystatin C; 
sCr, serum creatinine; BNP, brain natriuretic peptide; CRP, C-reactive Protein; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
*P  value for difference between eGFRMDRD ≥60 mL/min per 1.73 m
2 and eGFRMDRD <60  mL/min per 1.73 m
2.
Figure 1. Histogram of serum cystatin C concen-
trations. Patients with eGFRMDRD <60 mL/min per 
1.73 m2 are projected in darker shade. eGFR indi-
cates estimated glomerular filtration rate.
and were not deemed to be at higher risk of MACE based 
on their eGFRMDRD. However, CysC-based measurements 
showed they were at risk. This is particularly apparent when 
comparing different measures of renal function in those with 
eGFRMDRD ≥60 mL/min per 1.73 m2, indicating a progres-
sive increased risk for future MACE with increasing quartiles 
of CysC and decreasing quartiles of eGFRCysC (P=0.002 and 
0.001, respectively) but not other measures (online-only Data 
Supplement Figure).
In different multivariate Cox proportional hazard models 
(each containing one measure of renal function), all renal 
function measures (except urea) were associated with higher 
risk of future MACE when adjusted for BNP (model 1) and 
other risk factors (model 2) (Table 3). Figure 4 depicts the 
additive value of CysC and BNP in overall risk prediction. 
Patients in the highest tertile of both variables had a 45% risk 
to experience death, MI, or stroke after 3 years compared 
with only 12% when both variables were in the lowest tertile 
(P<0.0001).
Discussion
There is a wealth of literature demonstrating the ability of 
CysC as a reliable and sensitive measure of renal dysfunction, 
and we and others have demonstrated the prognostic value 
of CysC in the setting of acute heart failure,10,12–14 as well as 
in stable chronic heart failure.9,15–17 However, the majority 
of studies have been limited to relatively small sample sizes 
that precluded adequately powered subgroup analyses with 
covariate adjustments to shed the light on how to best use this 
measure of renal function in the clinical setting. As the larg-
est study looking at the clinical use of CysC in stable chronic 
heart failure using contemporary statistical methodologies, we 
observed that elevated CysC may identify a large number of 
patients at increased cardiovascular risk with what was previ-
ously labeled as preserved renal function (eGFRMDRD >60 mL/
min per 1.73 m2). Combining CysC with BNP provides excel-
lent risk stratification, with an incidence of 12% of MACE at 
3 years when both variables were in the lowest tertiles, versus 
an incidence of 45% of MACE at 3 years when both vari-
ables were in the highest tertiles. Taken together, our results 
imply that there is incremental prognostic value of CysC in 
patients with chronic stable heart failure, particularly in those 
with relatively preserved renal function based on creatinine-
based estimates. This demonstrates that even in the setting of 
mild renal dysfunction there seems to be heightened risk for 
adverse cardiovascular outcomes.
Our findings corroborated prior studies9,15 that suggested 
CysC may improve overall risk prediction in heart failure. The 
limitations of sCr’s reciprocal relationship with GFR are well 
known, largely because of variable production (as a function of 
age, sex, muscle mass, and ethnicity), diet, and tubular secre-
tion.18 Creatinine-based equations try to correct for this by 
including determinants of muscle mass (age, weight, race, sex) 
in their formulas.19 The equations were developed in patients 
with chronic kidney disease, where they are reasonably accu-
rate.20 It remains intriguing to see, in this and other studies,21 
that CysC is consistently better in risk prediction, whereas it 
is either equivalent or only slightly improves eGFRMDRD esti-
mation.7 We see 2 potential explanations for this observation. 
Table 2. AUC-ROC for Different Measures of Renal Function 




eGFR ≥60 mL/min 
per 1.73 m2
(n=615)
eGFR <60 mL/min 
per 1.73 m2
(n=208)
eGFRMDRD 0.615 0.529 0.550
CysC 0.648 0.600 0.586
(P=0.07) (P=0.006) (P=0.18)
eGFR
CysC 0.652 0.603 0.589
 (P=0.01) (P=0.001) (P=0.18)
eGFR
sCr+CysC 0.641 0.581 0.573
(P=0.02) (P=0.02) (P=0.25)
AUC-ROC indicates area under the curve-receiver operating characteristics; 
MACE, major adverse cardiovascular events; eGFR, estimated glomerular 
filtration rate; CysC, cystatin C; sCr, serum creatinine.
MACE=death, myocardial infarction, or stroke.
P  values are for comparison with eGFRMDRD.
Table 3. Uni- and Multivariate Cox Proportional Hazard Models for Different Renal Measures as Predictors of MACE
Log-Transformed
Cox Proportional Hazard
Unadjusted Model 1* Model 2†
Hazard Ratio† P  Value Hazard Ratio† P  Value Hazard Ratio‡ P  Value
Urea 1.40 (1.22–1.59) <0.0001 1.25 (1.09–1.42) 0.0016 1.14 (0.96–1.28) 0.17
Creatinine 1.34 (1.21–1.48) <0.0001 1.22 (1.09–1.35) 0.0008 1.17 (1.03–1.32) 0.015
eGFR
MDRD 0.72 (0.65–0.80) <0.0001 0.80 (0.72–0.90) 0.0002 0.85 (0.75–0.96) 0.012
Cystatin C 1.45 (1.30–1.60) <0.0001 1.29 (1.15–1.44) <0.0001 1.20 (1.05–1.36) 0.0085
eGFR
CysC 0.69 (0.62–0.77) <0.0001 0.77 (0.68–0.87) <0.0001 0.82 (0.73–0.94) 0.006
eGFRsCr+CysC 0.70 (0.63–0.78) <0.0001 0.78 (0.70–0.88) <0.0001 0.83 (0.73–0.94) 0.006
MACE indicates major adverse cardiovascular events; eGFR, estimated glomerular filtration rate; CysC, cystatin C; sCr, serum creatinine; BNP, brain natriuretic 
peptide.
P value for log(BNP) <0.001 in every model.
*Model 1 is adjusted for log-transformed BNP.
†Model 2 is further adjusted for age, body mass index, history of coronary artery disease, history of diabetes mellitus, hemoglobin, and high-sensitivity 
C-reactive protein.
‡Hazard ratios are per 1 SD (urea 12.7, creatinine 0.89, eGFRMDRD 26.2, cystatin C 0.73, eGFRCysC 23.7, eGFRsCr+CysC 24.8).
First, CysC and derived equations are significantly better than 
sCr-derived equations in estimating GFR in the nonchronic 
kidney disease population. This is well possible because in 
these nonchronic kidney disease populations (elderly, heart 
failure, coronary patients), mean GFR is higher, patients are 
older, and have more comorbidities. Current creatinine-based 
GFR equations tend to be less accurate in the higher GFR 
ranges as nicely demonstrated in the diabetic population and 
the heart failure population.4,22,23 In addition, in the aforemen-
tioned settings, the dependence of creatinine on factors other 
than GFR (muscle mass, diet, and general health condition) 
becomes more and more important. These influences are not 
captured by correcting for age, sex, and race. A second possi-
bility is that CysC represents other factors aside renal impair-
ment. There is indeed some mechanistic evidence to suggest 
that CysC, being an inhibitor of cysteine proteases, may be 
intricately involved in the pathogenesis of atherosclerosis.24 
In addition, it has been shown that the levels of CysC can be 
influenced by inflammation, glucocorticoid use, and thyroid 
function.25 All this may explain why the incremental prognos-
tic value of CysC is mainly confined to those with relatively 
preserved renal function, whereas the role of measuring CysC 
in those with already impaired renal function as determined by 
sCr-based estimates is limited.
We have also applied for the first time the CysC-derived 
equation for estimating GFR in the heart failure population 
and found eGFRCysC to be reliably predictive of long-term 
outcomes (and potentially superior to eGFR
sCr+CysC). The 
observation that the eGFRCysC equation further improved risk 
prediction compared with CysC was unexpected. In fact, the 
correlation between CysC and eGFRCysC equation is very high 
(r=0.98), and the equation only reclassified 14% of patients in 
a different quartile. However, in addition to a play of chance, it 
remains possible that adjusting for age, sex, and race is impor-
tant in this population. Interestingly, the addition of creatinine 
to the CysC-based equation (eGFR
sCr+CysC) weakened the prog-
nostic ability again. This suggests that, once GFR is estimated 
on the base of CysC, any potential improvement of GFR esti-
mation by adding sCr is outweighed by its association with 
muscle mass or general health condition.
One important observation from our study is the fact that 
one third of subjects in the subset with eGFRMDRD ≥60 mL/min 
per 1.73 m2 (or up to one quarter of subjects in our entire 
study cohort) may demonstrate an elevated CysC level that 
Figure 2. Forrest plots (unadjusted) for quartiles of different measures of renal function. Hazards ratio compared with reference for quartiles 
of urea, cystatin, creatinine (all in mg/dL), as well as estimated glomerular filtration rate (eGFR) equations (all in mL/min per 1.73 m²). CysC 
indicates cystatin C.
is associated with heightened risk for future adverse cardiac 
events. This represents a relatively large population at risk. 
In this subgroup, CysC and CysC-derived equation were the 
only measures of renal function that stratified risk of adverse 
events. Taken together, the present data suggest that a decrease 
in GFR increases cardiovascular risk throughout its spectrum 
without a clear normal cut-off by sCr or sCr-based equations.
The current use of CysC in clinical practice is limited, 
despite its approval, clinical availability, and extensive 
nephrology and epidemiology literature to support its value. 
This is, in part, because no prior studies have relied on CysC 
as an inclusion criterion for treatment decisions, and limited 
therapeutic studies have provided analyses to test the dif-
ferential impact of interventions in high versus low CysC 
subgroups. Nevertheless, the ability to identify a vulnerable 
population in a cohort of chronic stable heart failure is an 
opportunity to test therapeutic strategies that may potentially 
provide incremental benefit to existing therapies. Current 
clinical trials have used sCr-based cut-off values as exclusion 
criterion either because of therapeutic contraindications or to 
remove confounding because of concomitant end-organ dys-
function that may indirectly affect the demonstration of thera-
peutic efficacy. In contrast, natriuretic peptide-based cut-off 
values, identifying a more at-risk subpopulation, have been 
increasingly used in clinical studies to facilitate the successful 
demonstration of the benefits of drug therapy (such as eplere-
none in mild heart failure).26 At the other end of the spectrum, 
post hoc subgroup analysis has implied that lower rather than 
higher natriuretic peptide levels may demonstrate therapeu-
tic benefits of statin therapy in ischemic cardiomyopathy.27 
Figure 4. Risk stratification in patients with heart 
failure according to tertiles of cystatin C and 
brain natriuretic peptide (BNP). The risk of the 
combined outcome (death, myocardial  infarction, 
stroke) increases from 12.3% in patients with 
both biomarkers in the lowest tertile to 44.8% in 
patients with both biomarkers in the highest tertile 
(P<0.0001).
Figure 3. Kaplan-Meier curves for death/myocardial infarction (MI)/stroke according to quartiles of cystatin C (CysC) (A) and eGFRCysC 
(B). eGFR indicates estimated glomerular filtration rate.
Based on the interrelationship between CysC and BNP, it is 
conceivable to identify those with elevated natriuretic pep-
tides and elevated CysC levels to test therapeutic strategies 
toward combined or separate targets in the setting of mild 
heart failure.
Study Limitations
The biggest limitation of this study is that there was no 
direct gold standard measurement of GFR (eg, inulin or 
125I- iothalamate clearance), yet recent reports of relation-
ships between iothalamate-derived GFR measures and CysC 
or eGFRMDRD have been reported.17 Consequently, it remains 
speculative to state that the CysC-derived equation may bet-
ter reflect GFR in the heart failure population. Second, there 
was some degree of selection bias because the population 
studied included patients undergoing elective cardiac cath-
eterization for symptom evaluation, and there were no pro-
spective outcomes regarding heart failure hospitalizations. 
Furthermore, the particle-enhanced turbidimetric immu-
noassay used to determine CysC levels may have resulted 
in values that are 20% to 30% higher than in the common 
particle-enhanced nephelometric immunoassay method.28 
Similarly, the eGFRCysC equation was derived with CysC val-
ues determined by the nephelometric and not turbidimetric 
method, thus resulting in lower absolute eGFRCysC values. 
However, this should not alter the correlation of CysC or 
eGFRCysC with other measures of renal function, nor its risk 
predictive ability. Finally, we were not able to examine how 
CysC adds to other renal biomarkers (eg, neutrophil gelati-
nase-associated lipocalin) that reflect complementary renal 
processes (eg, tubular injury).
Conclusion
CysC is a strong predictor of adverse events in stable chronic 
heart failure, independent of traditional risk factors and BNP. 
CysC and its derived equation to eGFR add significant prog-
nostic value to creatinine, predominantly in patients with rela-
tively preserved renal function.
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